What specific action is Pfizer taking in response to Germany's proposed drug pricing policies, according to CEO Albert Bourla's letter?

Pfizer is reviewing 'the timing, scope, and future prioritization of certain planned investments in Germany' as a direct response to the German government's policy proposals that would lower drug prices, which Bourla stated call into question the predictability required for long-term investment decisions in the pharmaceutical industry.

How does Pfizer's reaction compare to recent actions by other pharmaceutical companies in Germany, as mentioned in the news?

Pfizer's review of its German investment plans follows similar reactions from other major drugmakers: U.S.-based Eli Lilly announced it would halve its $2.3 billion investment in Germany, and German company Boehringer Ingelheim scrapped its €900 million investment plans—both citing the German government's planned healthcare cost-cutting measures, including drug price reductions.

Pfizer CEO warns German investment at risk over drug pricing policies

Jun 10, 2026

Pfizer is reviewing planned investments in Germany following CEO warnings that government drug price cuts threaten long-term predictability. This mirrors similar investment halts by Eli Lilly and Boehringer Ingelheim due to healthcare cost-cutting measures.

reuters

2026-02-12

UK Law Firms Eye Legal Action Against Pfizer Over Contraceptive-Linked Brain Tumours

2026-06-10

Pfizer CEO warns German investment at risk over drug pricing policies

2026-06-18

Pfizer CFO Dave Denton to step down, leave company in August

2026-06-23

China Outpacing Europe in Drug Innovation and Development, Pfizer Executive Says

2026-07-10

Polish Air Traffic Control Faces Funding Freeze Over COVID Vaccine Ruling